Adbry and Rinvoq drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Adbry (tralokinumab) and Rinvoq (upadacitinib). Common drug interactions include eczema among females and conjunctivitis among males.

The phase IV clinical study analyzes what interactions people have when they take Adbry and Rinvoq. It is created by eHealthMe based on reports of 19 people who take the same drugs from the FDA, and is updated regularly.

What is Adbry?

Adbry has active ingredients of tralokinumab. eHealthMe is studying from 1,899 Adbry users. Check the latest studies of Adbry.

What is Rinvoq?

Rinvoq has active ingredients of upadacitinib. eHealthMe is studying from 47,375 Rinvoq users. Check the latest studies of Rinvoq.

On Jul, 04, 2026

19 people who take Adbry and Rinvoq together, and have interactions are studied.

What are the common drug interactions of Adbry and Rinvoq, by gender? *:

female:

Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters)
Coronary arterial stent insertion
Rash
Drug ineffective
Skin exfoliation (removal of the oldest dead skin cells)
Skin fissures (a crack in the skin)
Squamous cell carcinoma of skin (a cancer of a kind of epithelial cell, the squamous cell. these cells are the main part of the epidermis of the skin)
Fall
Varicella virus test positive
Alopecia (absence of hair from areas of the body)

male:

Conjunctivitis (pink eye)
Cardiac disorder
Dermatitis atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder)
Discomfort
Gastrointestinal disorder (functional problems of gastrointestinal tract)
Injection site bruising
Ocular hyperaemia (an abnormally large amount of blood in eye)
Rash
Sleep disorder

What are the common drug interactions of Adbry and Rinvoq, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Dry skin
Pruritus (severe itching of the skin)
Rash

20-29:

Drug ineffective

30-39:

Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it)
Dermatitis atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder)
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters)

40-49:

n/a

50-59:

Squamous cell carcinoma of skin (a cancer of a kind of epithelial cell, the squamous cell. these cells are the main part of the epidermis of the skin)
Ocular hyperaemia (an abnormally large amount of blood in eye)
Scab (a hard coating on the skin formed during the wound healing)
Skin erosion (a discontinuity of the skin)
Skin fissures (a crack in the skin)
Skin lesion
Transient ischaemic attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow))
Alopecia (absence of hair from areas of the body)
Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
Drug ineffective

60+:

Hospitalisation

What are the existing conditions these people have? *

Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 14 people, 73.68%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 2 people, 10.53%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 1 person, 5.26%
Neurodermatitis (a skin disorder characterized by long lasting itching and scratching): 1 person, 5.26%
Eye Disorder: 1 person, 5.26%
Dermatitis Allergic (inflammation of the skin due allergic reaction): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Adbry and Rinvoq?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously